Drug intelligence / Profile preview

MVP-202

Development stage: Preclinical
Lead developer: Multiverse Pharma

Overview

MVP-202 is a preclinical-stage blood-brain barrier (BBB) shuttle candidate developed by Multiverse Pharma. It is engineered to facilitate the delivery of therapeutic molecules into the central nervous system (CNS) by overcoming the restrictive nature of the BBB. While the specific molecular target and intended therapeutic cargo have not been disclosed, the asset is part of Multiverse Pharma's pipeline focused on enhancing the CNS penetration of biologics, likely utilizing receptor-mediated transcytosis mechanisms.

Other names: MVP-202MVP202MVP 202

Beyond the preview

Go deeper on MVP-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP-202.

Explore the full profile